A randomized, open-label, phase 3 study of gedatolisib fulvestrant ± palbociclib vs standard of care in HR /HER2−/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2)

Celcuity Inc. published this content on June 02, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 02, 2026 at 17:56 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]